Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BEAM
Strong SellSinkerBeam Therapeutics Inc. · Healthcare · United States · $3.0B · Avg Vol: $43M/d
COMPANY DESCRIPTION
Beam Therapeutics Inc. is a leading biotechnology company pioneering the development of precision genetic medicines using its proprietary base editing technology. This novel gene-editing platform enables targeted, single-base changes to DNA without cutting the double helix, offering a potential path to cure a wide range of genetic diseases. Beam holds a significant competitive advantage through its foundational intellectual property and broad pipeline, aiming for transformative therapeutic impact.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 60.9M | 377.7M | 63.5M | 139.7M | 31.9% | 156.0M | 48.6M | 62.7M | -33.0% |
| EPS | -4.13 | -1.72 | -4.58 | -0.81 | — | -0.69 | — | — | — |
| Shares | 71.3M | 81.6M | 83.6M | 101.7M | +42.8% | 103.3M | — | — | — |
| Debt | 179.0M | 172.7M | 161.4M | 154.1M | -4.9% | 247.4M | — | — | — |
| Equity | 733.5M | 981.3M | 733.5M | 1.2B | 19.1% | — | — | — | — |
| Op CF | 22.5M | -149.2M | -347.2M | -345.1M | — | -359.4M | — | — | — |
| Inv CF | -461.3M | 71.8M | 185.0M | -121.4M | — | — | — | — | — |
| Fin CF | 111.6M | 276.4M | 7.7M | 478.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BEAM are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BEAM | Beam Therapeutics Inc.(you) | $3.0B | 13 | Strong Sell |
| GPCR | Structure Therapeutics Inc. | $3.4B | 13 | Strong Sell |
| RCUS | Arcus Biosciences, Inc. | $3.7B | 14 | Strong Sell |
| ALMS | Alumis Inc. | $2.9B | 9 | Strong Sell |
| KOD | Kodiak Sciences Inc. | $2.4B | 12 | Strong Sell |
| MLYS | Mineralys Therapeutics, Inc. | $2.3B | 14 | Strong Sell |
| IMNM | Immunome, Inc. | $3.1B | 20 | Strong Sell |
| RARE | Ultragenyx Pharmaceutical Inc. | $2.5B | 8 | Strong Sell |
| TNGX | Tango Therapeutics, Inc. | $3.9B | 17 | Strong Sell |
| STOK | Stoke Therapeutics, Inc. | $2.0B | 13 | Strong Sell |
Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.3%